Recurrent Hypoglycemia Following Asparaginase Therapy for Lymphoid Malignancies in Childhood: The Texas Children's Hospital Experience
Authors:
- 29 July 2026
- journal article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (9)
Abstract
Background: Hypoglycemia is a rarely reported complication of asparaginase (ASP) therapy in children with acute lymphoblastic leukemia/lymphoma (ALL/LLy). We sought to identify risk factors and outcomes among patients with ASP‐induced hypoglycemia (AIH) at our institution. Methods: Retrospective cohort study using electronic medical records to identify all patients who received ASP and had diagnosis of hypoglycemia between June 1, 2017 and June 30, 2022. Demographic and clinically relevant data were collected. Results: A total of 672 patients received ASP, with 8% having AIH—defined by a measured low blood glucose level within 14 days of ASP administration and other causes of hypoglycemia excluded. Median age at ALL/LLy diagnosis was 4.4 years (inter‐quartile range [IQR]: 2.5–7.7) that was younger than a comparison cohort of patients without AIH (median 6.7 years, p value 0.01). Median BMI z ‐score was 0.50 (IQR: −0.46 to 0.95). Initial hypoglycemia event was during Induction therapy in 71%, with a median of 11 days (IQR: 6–15) from ASP to hypoglycemia diagnosis. Median duration of the hypoglycemia episode was 11 days (IQR: 7–19). Recurrent hypoglycemia with subsequent ASP doses occurred in 84% of patients, with a median duration of 14 days (IQR: 8–21). Overall survival of the AIH cohort was 80% (85% if limited to patients with newly diagnosed ALL/LLy), with 3‐year median follow‐up. In univariate analysis, hypoglycemia severity was not associated with age, sex, ethnicity, or weight. Conclusion: AIH is relatively common with no clear risk factors besides younger age. It can recur and become more severe with longer duration. AIH screening and management should be implemented.Keywords
All Related Versions
This publication has 25 references indexed in Scilit:
- Hyperinsulinism‐induced hypoglycemia secondary to asparaginase Erwinia chrysanthemi (recombinant)‐rywn chemotherapy in a pediatric AML patientPediatric Blood & Cancer, 2024
- Late-onset Cognitive Impairment and Modifiable Risk Factors in Adult Childhood Cancer SurvivorsJAMA Network Open, 2023
- Hyperglycemia during induction therapy for acute lymphoblastic leukemia is temporally linked to pegaspargase administrationPediatric Blood & Cancer, 2021
- Prevention of mercaptopurine‐induced hypoglycemia using allopurinol to reduce methylated thiopurine metabolitesPediatric Blood & Cancer, 2018
- Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli‐Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic LeukemiaPediatric Blood & Cancer, 2015
- Steroid‐induced diabetes: a clinical and molecular approach to understanding and treatmentDiabetes/Metabolism Research and Reviews, 2013
- Children's Oncology Group's 2013 blueprint for research: Cancer control and supportive carePediatric Blood & Cancer, 2012
- Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemiaPediatric Blood & Cancer, 2009
- Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemiaPediatric Blood & Cancer, 2008
- ACTH deficiency in childhood cancer survivorsPediatric Blood & Cancer, 2005